Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXT-MS personalized extended interval natalizumab dosing study
NL-OMON59760Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Primary endpoint: Radiological disease activity. Started Jul 2024; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON59760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59760.